2022 Patient Support Vendor Directory

New research finds that nearly half of the racial and ethnic disparities in outpatient COVID-19 antiviral prescriptions stem from encounter-level care barriers, such as limited access to rapid tests and telehealth, which emphasizes the need for systemic and practice-level reforms.

Renier Brentjens, MD, PhD outlines the evolution of the space, while offering ways to boost patient access to these treatments.

Through a strategic, non-profit agreement, Gilead will supply up to two million doses of the long-acting HIV prevention drug across 120 low- and lower-middle-income countries over the next three years.

Brandon Newman joins The Pharmaceutical Commerce Podcast to discuss the evolving role of PBMs, including the importance of drug price transparency.

As drug development increasingly targets multiple indications, pharma companies must make strategic branding decisions—balancing regulatory requirements, market dynamics, and patient safety—to choose between single-brand or multi-brand approaches.

Access to the GLP-1 will be streamlined, and starting July 1, will result in a limited-time $299 price for eligible self-pay patients.